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Cold-induced adaptive thermogenesis has gained considerable interest 
due to the ‘rediscovery’ of BAT in adult humans in 2009 (refs. 1–3). In 
response to these findings, activation of human BAT has been proposed 
as a potential treatment for type 2 diabetes (T2D) because such activation 
leads to the dissipation of energy as heat, which is expected to not only 
increase energy expenditure but also boost the oxidation of triglycerides 
and glucose as substrates. Thus it is expected that patients with T2D 
treated in this way would display not only weight loss but also improve-
ments in lipid and glucose homeostasis4,5. Indeed, in rodents enhanced 
BAT activity has been shown to prevent the development of obesity and 
diabetes under obesogenic conditions6. We7 and others8,9 have recently 
shown that chronic cold exposure (cold acclimation) leads to increases 
in both BAT quantity and activity in humans, suggesting that BAT can 
be recruited upon cold acclimation. Here we investigated whether cold 
acclimation for 10 d could be used to recruit BAT and improve glucose 
homeostasis in eight individuals with T2D (Supplementary Table 1). 
Body weight and clinical blood parameters were unaffected by cold accli-
mation (Supplementary Table 2), and thyroid-stimulating hormone 
(TSH) concentrations decreased while free thyroxine (T4) concentra-
tions increased after cold acclimation (Supplementary Table 2).
As a measure of BAT activity, we determined acute cold-induced 
2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) uptake by positron emission 
tomography–computed tomography (PET-CT) scanning (Fig. 1a,b). Upon 
cold acclimation, [18F]FDG uptake (standardized uptake values (SUV)max 
(data not shown) and SUVmean) in the supraclavicular BAT region 
increased in all subjects (Fig. 1c). Also, CT radio density (in Hounsfield 
units) of the BAT depot increased in 7 out of 8 subjects after cold acclima-
tion (Fig. 1d), suggesting that triglyceride content was reduced, indicative 
of BAT activation10. However, we noted that even after cold acclimation 
the observed [18F]FDG uptake values in BAT in the T2D patients in our 
study were very low compared with those in the literature, which were for 
young, healthy subjects7,11. We also measured cold-induced [18F]FDG 
uptake in several muscle groups from the cold-acclimated patients. Skeletal 
muscle [18F]FDG uptake tended to increase in most of the investigated 
muscle groups, and the resulting average skeletal muscle [18F]FDG uptake 
was indeed increased after cold acclimation (Fig. 1e,f).
We next examined whether glucose uptake in other adipose tissue 
depots increased upon cold acclimation, which could indicate ‘beig-
ing’ (conversion of white adipose tissue (WAT) into adipose tissue 
containing UCP1-expressing adipocytes). However, [18F]FDG uptake 
was unaffected by cold acclimation in WAT depots, such as subcutane-
ous and visceral fat (Fig. 1e). We also performed microarray analysis 
in subcutaneous WAT biopsies from the human subjects taken before 
and after 10 d of cold acclimation and compared it to WAT obtained 
from cold-acclimated mice. No signs of beiging could be detected in 
the human WAT samples, and most genes identified as beiging mark-
ers were unaffected by the cold acclimation (Fig. 1g). Together these 
results indicate that after cold acclimation glucose uptake specifically 
increases in the supraclavicular BAT depot upon acute cold exposure, 
but BAT activity remains very low in these individuals.
We previously showed that activation of BAT by acute mild cold 
exposure correlates with cold-induced nonshivering thermogenesis 
(NST)7,12 and that NST increases upon cold acclimation in lean, healthy 
subjects7. Here we found that after, but not before, cold acclimation, 
acute mild cold exposure increased energy expenditure compared 
to energy expenditure measured in the thermoneutral zone (TNZ) 
(Fig. 1h), indicating increased capacity for NST upon cold acclimation. 
To investigate adaptation to the cold, we determined subjective ratings 
for sensation, thermal comfort and shivering. All ratings were improved 
at day 10 of cold acclimation compared to day 3, which was the first 
day with 6 h of cold exposure (Supplementary Fig. 1). Subjective 
ratings of hunger, fullness and satiety before and after lunch did not 
differ between day 10 and day 3 (data not shown). Mean skin and core 
temperatures, skin blood flow and blood pressure during cold exposure 
were unaffected by cold acclimation (Supplementary Table 3).
To investigate whether cold acclimation improved glucose homeo-
stasis in individuals with T2D, we used hyperinsulinemic-euglycemic 
clamps, the gold-standard technique, to determine insulin sensitivity 
before and after cold acclimation. Of note, clamps were performed 
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at thermoneutrality. Insulin sensitivity was markedly increased after 
cold acclimation as indicated by on average a 43% increase in the glu-
cose infusion rate during the clamp (Fig. 2a). In fact, the increase in 
insulin sensitivity even exceeded the improvements in insulin sensitiv-
ity that are seen upon long-term exercise training13, which is generally 
considered to be the best strategy to prevent or treat T2D. Improved 
whole-body insulin sensitivity was mainly accounted for by a marked 
increase in insulin-stimulated glucose disposal (Fig. 2b), reflecting 
improvement of peripheral insulin sensitivity. Basal endogenous 
glucose production (EGP) was not affected by cold acclimation, 
but insulin-induced suppression of EGP, reflecting hepatic insulin 
sensitivity, tended to improve upon cold acclimation (Fig. 2c and 
Supplementary Table 4). After cold acclimation nonesterified fatty 
acid concentrations were lower during the clamp (Fig. 2d), which indi-
cated improved adipose tissue insulin sensitivity14. Metabolic flexibility, 
the ability to shift from predominantly fat oxidation in the fasted state 
to glucose oxidation upon insulin stimulation, also tended to 
increase (data not shown), most likely as a reflection of improved 
insulin-stimulated glucose uptake into skeletal muscle15.
Because the increase in insulin sensitivity was much more pronounced 
than anticipated and the activity of BAT remained very low in the treated 
individuals, we performed detailed analyses of skeletal muscle biopsies 
obtained after an overnight fast, both before and after 10 d of cold accli-
mation. As mitochondrial function is a main determinant of insulin 
sensitivity in individuals with T2D16, we first examined whether cold 
acclimation altered skeletal muscle mitochondrial oxidative capacity 
and/or leak respiration. However, none of the mitochondrial respiration 
states were affected by cold acclimation (Supplementary Fig. 2a–e). 
Oxidative phosphorylation complexes and PGC-1α protein content, 
markers of mitochondrial content and biogenesis, respectively, were 
unaffected by cold acclimation (Supplementary Fig. 2f,g). Skeletal mus-
cle fat content was also unaffected by cold acclimation (Supplementary 
Fig. 2h). It was recently suggested that sarcolipin may regulate futile Ca2+ 
cycling in skeletal muscle and contribute to nonshivering thermogen-
esis17. However, the protein contents of sarcolipin and the sarcoendo-
plasmic reticulum calcium-transporting ATPase (Serca) isoform Serca2 
were unchanged upon cold acclimation (Supplementary Fig. 2i,j), 
although sarcolipin protein expression correlated with NST after cold 
acclimation (NST (J s−1 kg−1), r = 0.893, P = 0.007).
Skeletal muscle insulin sensitivity can be more directly affected 
by enhancement of the insulin-signaling cascade or by activation 
of AMPK18. We therefore examined biopsies taken before the 
hyperinsulinemic-euglycemic clamp to determine whether insulin 
signaling in skeletal muscle was affected by cold acclimation. Notably, 
phosphorylation of the serine-threonine kinase AKT at both Thr308 (data 
not shown) and Ser473 (Fig. 2e), as well as total AKT (data not shown), 
were unaffected by cold acclimation. Furthermore, phosphorylation 
of the Rab GTPase–activating protein AS160 was also unaffected by 
cold acclimation (Fig. 2f). We subsequently examined whether altered 
AMPK activation could contribute to the enhanced insulin sensitivity. 
However, total AMPK content (data not shown), phosphorylation 
of AMPK (p-AMPK; from 1,600 ± 408 to 1,598 ± 124 AU, n = 7, 
P > 0.05; data are mean ± s.e.m.) and p-AMPK/AMPK ratio (Fig. 2g) 
were unaffected by cold acclimation. In skeletal muscle, GLUT1 and 
GLUT4 are both involved in glucose uptake. Notably, while GLUT1 
protein content was unaffected by cold acclimation (from 0.72 ± 0.11 
to 0.63 ± 0.08 AU, n = 7, P > 0.05; data are mean ± s.e.m.), we observed 
that total GLUT4 protein content tended to increase after 10 d of cold 
acclimation (Fig. 2h). Subsequently, we performed immunostain-
ing of GLUT4 on muscle biopsy sections taken before the clamp to 
investigate the subcellular distribution of GLUT4 within the muscle 
cells. Whereas before cold acclimation GLUT4 was evenly distributed 
over the muscle cell, the pattern was clearly different after cold accli-
mation, with pronounced staining of GLUT4 at the cell membrane 
(Fig. 2i)—indicative of translocation of GLUT4 to the membrane to 
facilitate glucose uptake—occurring even under basal conditions. We 
quantified GLUT4 localization, which revealed an on average 60% enrich-
ment of GLUT4 in cell membranes after cold acclimation (Fig. 2j).
The observation of increased GLUT4 in the membrane is consistent 
with the higher [18F]FDG uptake in skeletal muscle after cold acclimation 
(Fig. 1e,f). Therefore, our data suggest that cold acclimation leads to an 
enrichment of GLUT4 at the sarcolemma, which may facilitate the uptake 
of glucose. This GLUT4 translocation could not be explained by AMPK 
activation or improved insulin signaling. Also, subjects did not report 
Figure 1 Glucose uptake in the supraclavicular BAT region before and after 
cold acclimation and WAT beiging. (a) [18F]FDG-PET images after acute cold 
exposure in one representative individual of the eight in the study before 
(left) and after (right) cold acclimation. Black arrows indicate supraclavicular 
BAT activity. (b) Transversal CT, PET and PET-CT fusion slices of the 
supraclavicular region showing [18F]FDG uptake in BAT locations (white 
arrows) in the same individual as in a. (c,d) Cold-induced glucose uptake 
(expressed as SUVmean) (c) and CT radio density (in Hounsfield units) (d) in 
the supraclavicular BAT region in all individual subjects. (e) Cold-induced 
glucose uptake in the supraclavicular BAT region, subcutaneous (WATsubc) 
and visceral WAT (WATvisc), liver, brain and upper-body skeletal muscle (SM). 
n = 8, *P < 0.05; error bars, mean ± s.e.m. (f) Cold-induced glucose  
uptake in individual skeletal muscle groups used to calculate average SM 
uptake in e. Er. spinae, erector spinae; Lev. scapulae, levator scapulae.  
n = 8; error bars, mean ± s.e.m. (g) Gene expression changes of selected 
genes involved in thermogenesis and/or beiging, or suggested as marker 
genes for beige adipose tissue, in subcutaneous WAT of human subjects with 
T2D (right column) and subcutaneous WAT from mice subjected to either 
10 d (left column; GSE51080) or 7 d (middle column; GSE13432) of cold 
exposure (~5 °C). P values represent intensity-based moderated t-statistic 
(IBMT)-regularized paired t-test raw P values. (h) Energy expenditure in 
thermoneutral conditions and upon acute cold exposure. TNZ, thermoneutral 
zone. n = 8; comparisons between data before and after cold acclimation 
or between thermoneutral and mild cold conditions were analyzed using 
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overt shivering in the final days of the cold acclimation and enhanced 
skeletal muscle GLUT4 translocation after cold acclimation was observed 
in the overnight-fasted, thermoneutral state. Therefore, alternative mecha-
nisms need to be explored: it has recently been proposed that β-adrenergic 
stimulation is able to activate GLUT4 translocation19, and daily cold 
exposure may increase sympathetic activity. Alternatively, it has recently 
been shown that BAT may release endocrine factors that can engage 
other metabolic tissues20, and it would be worth exploring if some of these 
endocrine factors have insulin-sensitizing effects on skeletal muscle.
In conclusion, our findings indicate that cold acclimation for 10 d has 
very marked positive effects on whole-body and skeletal muscle insulin 
sensitivity and thereby provide a new avenue to improve the metabolic 
health of patients with T2D.
MeTHods
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Gene Expression Omnibus: microarray data have 
been deposited with accession number GSE67297.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Figure 2 Insulin sensitivity and skeletal muscle GLUT4 localization  
before and after cold acclimation. (a) Individual data (left) and group  
mean ± s.e.m. (right) for glucose infusion rate (GIR), corrected for body  
weight, during hyperinsulinemic-euglycemic clamp; n = 8. (b) Insulin- 
stimulated glucose disposal (Rd), as a combination of glucose oxidation  
(CHOox) and nonoxidative glucose disposal (NOGD); n = 8. (c) Basal  
(non–insulin-stimulated) endogenous glucose production (EGP; left)  
and insulin-induced suppression of EGP (% ∆EGP) (right); n = 8.  
(d) Plasma nonesterified fatty acid (NEFA) concentrations during the  
hyperinsulinemic-euglycemic clamp; n = 8. (e–h) Western blot data for  
phosphorylation of AKT at Ser473 (e), phosphorylation of AS160 (f),  
ratio of phosphorylated AMPK (p-AMPK) and AMPK (g) and GLUT4  
(P = 0.063) (h), including representative blots of two individuals  
with T2D, in non–insulin-stimulated skeletal muscle biopsies; n = 7.  
(i) Representative images (of 3–5 images per individual) of GLUT4  
immunostaining on 5-µm-thick fresh-frozen non–insulin-stimulated skeletal  
muscle tissue sections from three individuals in the study. Scale bars,  
60 µm. (j) Quantification of average GLUT4 staining intensities at the  
sarcolemma and the cytosol (n = 7). Throughout, comparisons between  
data before and after cold acclimation were analyzed using Wilcoxon  






























Participants. Eight overweight male individuals with T2D (age 59.3 ± 5.8 years, 
body weight 92.0 ± 11.7 kg, BMI 29.8 ± 3.2 kg/m2, body fat 26.2 ± 4.0%) 
were included in this study. We performed a power calculation with insulin 
sensitivity as primary outcome. Based on an expected difference in insulin 
sensitivity of 20%, with a power of 0.80 and an α of 0.05 (2-sided), we 
calculated that 11 subjects would be needed (G*Power 3.1 software, F. Faul, 
E. Erdfelder, A.G. Lang and A. Buchner, University of Trier, Trier, Germany; 
http://www.gpower.hhu.de). Since the effects on insulin sensitivity were much 
more pronounced than anticipated in the power calculation, we terminated 
the study upon completion of all tests in eight subjects, in agreement with our 
external monitoring board. All subjects were screened for medical history, and 
exclusion criteria included uncontrolled hypertension, active cardiovascular 
disease, liver or kidney dysfunction, smoking and use of insulin, beta-blockers 
or other medication known to interfere with BAT function. Individuals 
included in the study were diagnosed with T2D, which was well controlled 
(HbA1c 50.1 ± 6.6 mmol/mol), at least 1.5 years before the start of the study. 
All subjects used metformin, and four subjects also used sulfonylurea agents 
(see Supplementary Table 1 for detailed subject characteristics). Studies were 
performed between January and September 2014.
Study approval. The study was approved by the Ethics Committee of Maastricht 
University Medical Center and all participants provided written informed con-
sent. Procedures were conducted according to the principles of the Declaration 
of Helsinki. Trial registration number: NTR4319.
Study design. Body composition was determined by dual X-ray absorptiometry 
(Discovery A, Hologic, Bedford, MA, USA). Subjects then started the 10-d cold 
acclimation intervention. Before and after 10 d of cold acclimation, an individu-
alized cooling protocol was performed, immediately followed by [18F]FDG-
PET–CT scanning (Gemini TF PET-CT, Philips, Eindhoven, the Netherlands) 
for quantification of BAT activity, as described previously7. On a separate day, an 
abdominal subcutaneous fat biopsy and a muscle biopsy from the vastus lateralis 
muscle21 was taken after an overnight fast. Subsequently, peripheral insulin 
sensitivity was assessed by a 3-h hyperinsulinemic-euglycemic clamp, performed 
at thermoneutrality. During the 10-d cold acclimation protocol, subjects were 
exposed to an environmental temperature of 14–15 °C for 10 consecutive days: 
2 h on day 1, 4 h on day 2, and 6 h on days 3 through 10. On day 11 after the 
start, cold-induced BAT activity measurements were repeated (~2.5 h in mild 
cold). On the following day (day 12), subjects were again exposed to an envi-
ronmental temperature of 14–15 °C for 6 h, and this was followed by the second 
hyperinsulinemic-euglycemic clamp on day 13. Subjects were instructed to 
maintain their normal antidiabetic medication use throughout the whole accli-
mation period, except for the days on which the clamps were performed.
Subjects consumed standardized meals on the evenings before each 
experimental day and were asked to refrain from heavy exercise at least 48 h 
before each of these measurements.
Cold acclimation. During cold acclimation, subjects were dressed in shorts and 
T-shirts and remained sedentary while staying in the cold room. Food intake 
in the cold room was kept constant and subjects were instructed not to change 
their normal dietary regime outside the cold room. Hunger and satiety ques-
tionnaires were completed before and after lunch. At selected time points, blood 
pressure was monitored, VAS scales on sensation, thermal comfort and shivering 
were completed and incremental AUCs (iAUC) were calculated to determine 
subjective responses during cold acclimation7.
Individualized cooling and PET-CT imaging. Individualized cooling protocols 
were performed after a 4 h fasting period. Subjects were wrapped in a water-
perfused suit (ThermaWrap Universal 3166, MTRE Advanced Technologies Ltd, 
Yavne, Israel) and were measured at thermoneutrality for 45 min, after which 
they were cooled until a temperature just above their shivering point and mea-
sured for an additional 30 min at this temperature. Core and skin temperatures, 
heart rate, skin perfusion and energy expenditure were measured continuously 
and blood pressure was measured every 15 min during the cooling protocol, as 
described previously7. Nonshivering thermogenesis (NST) was calculated as the 
absolute increase (corrected for body weight) in energy expenditure upon acute 
mild cold exposure above basal metabolic rate (measured at thermoneutral-
ity). Subsequently, 74 MBq of [18F]FDG was injected intravenously. One hour 
after injection the PET-CT scanning protocol started with a low-dose CT scan 
(120 kV, 30 mAs). Directly hereafter, a static PET scan (6 to 7 bed positions, 
6 min per bed position) was performed22. All PET-CT scans were analyzed using 
PMOD software (version 3.0, PMOD Technologies, Zurich, Switzerland) by both 
the researcher (M.J.W.H.) and an experienced nuclear medicine physician (B.B.). 
Fixed volumes of interest (VOIs) were selected in the supraclavicular adipose 
tissue region (between −10 and −180 Hounsfield units [HU]), subcutaneous and 
visceral WAT, liver, brain and in the deltoid, biceps, triceps and erector spinae 
muscles, as described previously23. Additionally, 2.67cm3 VOIs were placed 
in the scalene, levator scapulae and psoas major muscles, and average uptake 
in these 7 muscle groups is presented as average skeletal muscle activity. The 
VOIs were used to compare [18F]FDG uptake (calculated as SUVmean) and HU 
between these tissues and between scans before and after cold acclimation.
Hyperinsulinemic-euglycemic clamp. Hyperinsulinemic-euglycemic 
(40 mU m−2 min−1) clamps were performed according to DeFronzo24, with 
primed infusion of [6,6-2H2]glucose (0.04 mg kg−1 min−1). Steele’s single-pool 
non–steady state equations25 were used to calculate rates of glucose appear-
ance (Ra), glucose disposal (Rd), nonoxidative glucose disposal (NOGD; mainly 
reflecting glycogen synthesis) and endogenous glucose production (EGP), as 
previously described26. Basal and insulin-stimulated substrate oxidation was 
measured by indirect calorimetry (Omnical, IDEE, Maastricht, the Netherlands) 
and calculated according to Frayn27.
Blood analysis. Blood samples were collected before and during the clamp 
(in the basal and insulin-stimulated states). Plasma metabolites were deter-
mined according to standard procedures. Plasma concentrations of glucose 
(ABX Glucose HK CP Radiometer, Horiba ABX) and nonesterified fatty acids 
(NEFA-HR set, Wako Chemicals) were determined on a Cobas FARA centrifugal 
spectrophotometer (Roche Diagnostica). Plasma insulin concentrations were 
quantified using an immunometric assay (Advia Centaur, Siemens Diagnostics). 
Serum TSH and T4, and plasma catecholamines, were analyzed as described 
previously7.
WAT microarray analysis. Abdominal subcutaneous WAT was rinsed from 
blood, snap frozen in melting isopentane and stored at −80 °C until analyzed. 
Gene expression analysis was performed by microarray and compared to 
publically available WAT microarray data sets from cold-acclimated mice.
RNA was purified from human fat biopsies using TRIzol (Life Technologies, 
Calsbad, CA, USA) followed by an additional round of purification with 
RNeasy Minikit columns (Qiagen, Venlo, the Netherlands). RNA quality was 
assessed using RNA 6000 nanochips on the Agilent 2100 bioanalyzer (Agilent 
Technologies, Amsterdam, the Netherlands). Purified RNA (100 ng) was labeled 
with the Affymetrix WT PLUS reagent kit (Affymetrix, Santa Clara, CA, USA) 
and hybridized to an Affymetrix Human Gene 1.1 ST array plate (Affymetrix, 
Santa Clara, CA, USA). Hybridization, washing and scanning were carried out 
on an Affymetrix GeneTitan platform according to the manufacturer’s instruc-
tions. Arrays were normalized using the robust multiarray average method28,29. 
Probe sets were defined according to Dai et al.30. In this method probes are 
assigned to Entrez IDs as a unique gene identifier. The P values were calcu-
lated using an intensity-based moderated t-statistic (IBMT)31. The microarray 
data have been submitted to the Gene Expression Omnibus (accession number 
GSE67297). Expression changes in the subcutaneous white fat depot of mice 
subjected to either 10 d or 7 d of cold exposure (~5 degrees) were extracted 
from publicly available microarray data sets (GSE51080 and GSE13432) using 
the analysis pipeline described above.
Ex vivo skeletal muscle mitochondrial respiration. A portion of the muscle 
biopsy was directly frozen in melting isopentane and stored at −80 °C until 
assayed. Another portion (~30 mg) was immediately placed in ice-cold pres-
ervation medium (BIOPS, OROBOROS Instruments, Innsbruck, Austria) and 
used for the preparation of permeabilized skeletal muscle fibers (~2.5 mg wet 





























oxygraph (OROBOROS Instruments) according to Hoeks et al.33. In separate 
experiments, mitochondrial leak respiration was measured as the residual 
respiration following addition of 1 µg/ml of the ATP synthase–inhibitor 
oligomycin, using pyruvate (5 mM) as a substrate (in the presence of 4 mM 
malate). All oxygen consumption measurements were performed in quadru-
plicate. One muscle biopsy failed after cold acclimation; therefore, values for 
7 subjects are presented.
Muscle biopsy analyses. Protein expression was determined by western 
blotting according to standard procedures. Primary antibodies (AKT, 
phospho-AKT(Ser473), phospho-AKT (Thr308), phospho-AS160, phospho- 
AMPK, AMPK(Thr172) and GLUT1; diluted 1:1,000) were all from Cell 
Signaling Technology, Bioké, Leiden, the Netherlands and were all detected 
using a horseradish peroxidase–conjugated secondary swine anti-rabbit IgG 
antibody (DAKO, Glostrup, Denmark; diluted 1:2,000) and measured using 
enhanced chemiluminescence (Pierce, Thermo Scientific, Rockford, IL, USA).
Primary antibodies directed against GLUT4 (Santa Cruz, BioConnect, 
Huissen, the Netherlands) UCP3, OXPHOS-cocktail, Serca2 ATPase (all from 
Abcam, BioConnect); PGC1α (Calbiochem, Darmstadt, Germany), sarcolipin 
(Millipore, Schiphol-Rijk, the Netherlands) and α-sarcomeric actin (loading 
control; Sigma, Zwijndrecht, the Netherlands) were detected using appropriate 
secondary antibodies conjugated with IRDye680 or IRDye800 and detected with 
the Odyssey Near Infrared System (Licor, Westburg, Leusden, the Netherlands). 
Intramyocellular lipid (IMCL) content was determined in fresh cryosections 
(5 µm) by Oil red O staining combined with fibertyping and immunolabeling 
of the basal membrane marker laminin, as described previously34.
For GLUT4 imaging, double immunofluorescence assays were performed 
on 5-µm-thick fresh-frozen tissue sections, which were fixated for 15 min with 
3.7% formaldehyde in PBS and then treated for 5 min with 0.5% Triton X-100 in 
PBS. Sections were incubated overnight at 4 °C with a mix of primary antibodies 
directed to GLUT4 (Santa Cruz, BioConnect, Huissen, the Netherlands) and 
laminin (Sigma, Zwijndrecht, the Netherlands). After three washing steps with 
PBS, Alexa Fluor555– and Alexa Fluor488–conjugated secondary antibodies 
were incubated for 45 min at room temperature. After a final washing step with 
PBS, sections were mounted in Mowiol. Images were observed using a Nikon 
E800 fluorescence microscope with NIS-elements Imaging Software (Nikon 
Europe BV, Amsterdam, the Netherlands) and were captured with identical 
exposure time and gain settings in ‘before’ and ‘after’ conditions. Without any 
adjustments with respect to color intensity, brightness or contrast, RGB-stacked 
images were quantified using the Plot Profile tool in ImageJ. Thus, we measured 
the intensity of GLUT4-dependent signals (16 bits) throughout the sections. 
Measured data on intensity were used to generate overlying plots of GLUT4 and 
laminin. The GLUT4-derived staining intensity at the membrane was quantified 
at multiple locations per individual (13.7 ± 2.9 locations before and 15.4 ± 3.2 
locations after cold acclimation, respectively) in randomly chosen cross- 
sections of muscle biopsies, and was divided over the mean GLUT4 intensity in 
10 pixels located in the cytosol of the very same cell. Thus, a score >1.0 implied 
that relatively more GLUT4 was detected in the membrane than in cytosolic 
regions and hence reflected GLUT4 translocation.
Statistical analysis. Statistical analyses were performed with PSAW Statistics 
20.0 for MAC (SPSS). Nonparametric paired-sample Wilcoxon signed-rank tests 
were used to compare findings before and after cold acclimation and between 
thermoneutral and mild cold conditions. Spearman rank correlations were 
used to identify correlations between variables. P values <0.05 were considered 
statistically significant.
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